key: cord-0714388-p2wfjk7a
authors: Wang, H.; Miller, J.; Verghese, M.; Sibai, M.; Solis, D.; Mfuh, K. O.; Jiang, B.; Iwai, N.; Mar, M.; Huang, C.; Yamamoto, F.; Sahoo, M. K.; Zehnder, J.; Pinsky, B. A.
title: Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance
date: 2021-04-23
journal: nan
DOI: 10.1101/2021.04.20.21255480
sha: 426dc0f84d92c3dce4f290e4d3a3dd8185fa38dd
doc_id: 714388
cord_uid: p2wfjk7a

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with concerning phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic response, but many laboratories do not have the resources to support population-level sequencing. We hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-throughput variant surveillance. We designed and analytically validated a one-step multiplex allele-specific reverse transcriptase polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R, E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area population. Between December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by genotyping RT-qPCR, with an assay failure rate of 2.8%. We detected 1,567 L452R mutations (38.7%), 34 N501Y mutations (0.84%), 22 E484K mutations (0.54%), and 3 (0.07%) E484K+N501Y mutations. The assay had near-perfect (98-100%) concordance with whole-genome sequencing in a validation subset of 229 specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants, among others. The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8% in December 2020 that increased to 62.5% in March 2021. We developed and clinically implemented a genotyping RT-qPCR to conduct high-throughput SARS-CoV-2 variant screening. This approach can be adapted for emerging mutations and immediately implemented in laboratories already performing NAAT worldwide using existing equipment, personnel, and extracted nucleic acid.

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with concerning 23 phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic 24 response, but many laboratories do not have the resources to support population-level sequencing. We 25 hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-26 throughput variant surveillance. 27 28 We designed and analytically validated a one-step multiplex allele-specific reverse transcriptase 29 polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R, 30 E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We 31 then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area 32 population. 39 The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8% in 40 December 2020 that increased to 62.5% in March 2021. (1-3) In particular, variants associated with increased transmission, virulence, or resistance 52 to host, vaccine, or antiviral immunity are of significant public health concern.(4-17) Other mutations 53 could also potentially impact diagnostic sensitivity.(18) Genomic surveillance that is representative of the 54 newly-infected population is therefore an important tool for pandemic response. Upper respiratory nucleic acid amplification tests (NAATs) are the mainstay of SARS-CoV-2 diagnosis. In 70 contrast to sequencing, nearly all laboratories offering NAATs have equipment and trained personnel for 71 nucleic acid extraction and real-time polymerase chain reaction. We therefore aimed to develop a highly-72 accessible spike genotyping NAAT for high-throughput and rapid screening of positive SARS-CoV-2 73 samples. We hypothesized that this assay would facilitate large-scale VOC/VOI screening and track 74 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To permit single reaction multiplexing, we designed primer sets and dual-labeled hydrolysis probes to 94 maximize each probe's mismatch-ΔTm while maintaining probe specificity and a sufficiently high 95 annealing temperature (Table S1 ). This 2-7°C decrease in each probe's annealing temperature (ΔTm) 96 when binding SARS-CoV-2 cDNA with a single nucleotide mismatch distinguishes mutant from wild-type 97 nucleic acid templates. Given the proximity between the E484K and N501Y mutations, two primer sets 98 (flanking L452R and E484K/N501Y, respectively) were designed with annealing temperatures similar to 99 or above probe annealing temperatures. 100 101 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. 1 ). Amplification curves from RT-154 qPCR were interpreted according to Table S4 , with example cases presented in Fig. S2 . A total of 174 155 specimens had amplification failure on initial RT-qPCR, either due to low viral load, amplification failure, 156 or reaction setup error. Among these specimens, 59 were successfully genotyped on repeat RT-qPCR 7 and are included in the analysis dataset, while the remaining 115 were unable to genotype, 158 corresponding to an assay failure rate of 2.8%. Among initial diagnostic specimens tested by RT-qPCR 159 with available C t values (3,142), median viral load was significantly lower among samples unable to 160 genotype (C t 28.8 vs 18.8, p<0.001). (Table 1) , 170 PPA of RT-qPCR for L452R, E484K, and N501Y were: 100% (95% CI 95-100%), 100% (95% CI 80-171 100%), and 100% (95% CI 86-100%), respectively (Table 2) Table 3 , and a phylogenetic tree of Nextstrain clades is presented in Fig. 2 . The 120 184 specimens which were wild-type by RT-qPCR were most commonly assigned lineages of B.1.2 (34%) 185 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. qPCR, 11 (79%) were P.2, 2 (14%) were B.1, and 1 (7%) was B.1.526 (Fig. 3) . The three specimens with (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.20.21255480 doi: medRxiv preprint more specific to variants of concern/interest and appear to be causally-associated with concerning 242 phenotypes. Another genotyping NAAT utilized a two-step approach combining the CDC-based As evidence of the feasibility of high-throughput testing, we rapidly implemented reflex genotyping RT-267 qPCR for positive specimens and screened more than 4,000 infections, thereby facilitating local 268 surveillance of L452R mutation emergence. Our results are consistent with a large-scale whole-genome 269 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 1) We developed and rapidly implemented a one-step multiplex allele-specific RT-qPCR assay to conduct 294 rapid and high-throughput SARS-CoV-2 variant screening in the San Francisco Bay Area. The assay had 295 near-perfect concordance with whole-genome next-generation sequencing and facilitates detection of all 296 common and uncommon variants of concern/interest harboring the L452R, E484K, or N501Y mutations. 297 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This study was not funded by any grants, scholarships, fellowships, or commercial entities. The authors 307 report no conflicts of interest related to this work. 308 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 23, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 23, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv 371 2021

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 381 202012/01 (B.1.1.7). ID 3779160. SSRN Scholarly Paper

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and 389 monoclonal antibodies

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral 393 Spike vaccines

Genetic Variants of SARS-CoV-2 May Lead to False Negative Results 395 with Molecular Tests for Detection of SARS-CoV-2 -Letter to

Risk assessment: SARS-CoV-2 -increased circulation of variants of concern and vaccine 399 rollout in the EU/EEA, 14th update. Eur Cent Dis Prev Control. 400 21. Weekly epidemiological update on COVID-19

Data, disease and diplomacy: GISAID's innovative contribution 402 to global health

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

STARD 2015: An Updated List of Essential Items for Reporting Diagnostic 433 Accuracy Studies

Ketre Kolukirik CZ. 435 2021. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations

A 438 Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS

PCR assay to 445 enhance global surveillance for SARS-CoV-2 variants of concern. preprint

Specific allelic 449 discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B

Early Release -Detecting Rapid Spread of SARS

CoV-2 Variants

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity